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ApcMin/+ tumours and normal 
mouse small intestines show linear 
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Topographical variations of metabolite concentrations have been reported in the duodenum, jejunum 
and ileum of the small intestine, and in human intestinal tumours from those regions, but there are 
no published metabolite concentrations measurements correlated with linear position in the mouse 
small intestine or intestinal tumours. Since DNA methylation dynamics are influenced by metabolite 
concentrations, they too could show linear anatomical variation. We measured metabolites by 
HR‑MAS 1H NMR spectroscopy and DNA cytosine modifications by LC/MS, in normal small intestines 
of C57BL/6J wild‑type mice, and in normal and tumour samples from ApcMin/+ mice. Wild‑type mouse 
intestines showed approximately linear, negative concentration gradations from the pylorus (i.e. 
the junction with the stomach) of alanine, choline compounds, creatine, leucine and valine. ApcMin/+ 
mouse tumours showed negative choline and valine gradients, but a positive glycine gradient. 
5‑Hydroxymethylcytosine showed a positive gradient in the tumours. The linear gradients we found 
along the length of the mouse small intestine and in tumours contrast with previous reports of discrete 
concentration changes in the duodenum, jejunum and ileum. To our knowledge, this is also the first 
report of a systematic measurement of global levels of DNA cytosine modification in wild‑type and 
ApcMin/+ mouse small intestine.
Several recent studies have shown topographical variations of metabolite concentrations in the intestines of nor-
mal  humans1,  rats2,3 and  mice4, and also in human tumours arising in different intestinal  regions5. These reports 
led us to investigate whether mouse intestinal cancer metabolism may also depend on the anatomical location 
of the tumour in the small intestine of the ApcMin/+ mouse, a widely-used model of gut tumorigenesis that spon-
taneously develops adenomas in the small and large  intestines6 which can be sampled from precise anatomical 
locations. This model was used to assess metabolic variations in both tumour and non-tumour tissues by HR-
MAS 1H  NMR7. The effect of anatomical location on metabolism of  ApcMin/+ adenomas has not been investigated.
We therefore performed HR-MAS 1H NMR on biopsies taken along the length of the small intestines from 
wild-type C57BL/6J mice and ApcMin/+ littermates. HR-MAS 1H NMR is less sensitive than mass spectrometry 
(hence the limited number of metabolites analysed herein) but it has the advantage that metabolites are assayed 
in the original sample, with no errors due to extraction, derivatisation or ionisation; also, the sample is unaf-
fected by the spectroscopic procedure, so the metabolite data can be paired to data from additional analyses. 
Because epigenetic changes associate with gene  activity8, cellular  proliferation9,10 and cancer cell  metabolism11 
we measured cytosine methylation and hydroxymethylation in DNA extracted from the tissue biopsies that had 
been used for the metabolite analysis.
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Results
The metabolite concentrations from wild-type C57BL/6J mice (WT), ApcMin/+ adenomatous tumours (Tumour) 
and from normal tissue adjacent to ApcMin/+ tumours (NAdj), plotted as a function of the distance of the sample 
from the pylorus, are shown in Figs. 1 and 2. Unexpectedly, the concentrations of several metabolites showed 
linear gradients throughout the length of the small intestine; these gradients were evident both in the intestinal 
tissues and in the tumours.
In the small intestines of WT mice there were statistically significant linear gradients from pylorus (high) to 
colon (low) in the concentrations of alanine, choline, t-Cho (choline + phosphocholine + glycerophosphocho-
line), creatine, t-Cr (creatine + phosphocreatine), leucine and valine (Table 1; Fig. 1). Five other metabolites, 
phosphocholine, glycerophosphocholine, glutamate, glycine and taurine, showed no significant gradients in the 
WT small intestine (Table 1).
Tumour tissues from ApcMin/+ mice showed choline, glycine and valine concentration gradients, depending on 
the position of the tumour in the small intestine. The choline and valine gradients were negative, with the high-
est concentrations closest to the pylorus, like those in the WT tissue samples. Uniquely among the metabolites 
studied, however, glycine in Tumour samples showed a gradient with a positive slope along the small intestine 
from pylorus (low) to colon (high) (Fig. 1; Table 1); all other metabolites in Tumour and WT samples, showed 
negative slopes.
We also studied tissue samples from normal tissues adjacent to the tumours in ApcMin/+ mice (Fig. 2; Table 1). 
These NAdj samples showed all the metabolite gradients we had found in WT samples (Fig. 1) except for t-Cho, 
which did not have a significant gradient. Only choline and valine displayed concentration gradients in all three 
tissues—WT, NAdj and Tumour (Table 1).
We then used a linear regression model to determine whether the slopes of the gradients were significantly 
different when we compared the WT vs NAdj and the Tumour vs NAdj graphs (Figs. 1, 2; Supplementary 
Table S1). None of the slopes of the metabolite gradients were significantly different in WT compared to NAdj 
tissues (Figs. 1, 2; Supplementary Table S1), but the gradients of choline, creatine and glycine were significantly 
different between Tumour and NAdj samples (Figs. 1, 2; Supplementary Table S1 statistically significant gradients 
shown in bold red).
In order to get an overview of the metabolomics of these samples, we also averaged the metabolite concentra-
tions along the whole of the small intestine and then compared the mean metabolite values between the WT and 
NAdj samples and also between the Tumour and NAdj samples (Supplementary Table S3; Fig. 3). In general, the 
ratios of Tumour metabolite concentration to NAdj concentration were very similar for 5 of the metabolites, with 
a mean of 1.37 + 0.16 (t-Cho 1.17, creatine 1.24; t-Cr 1.36; glycine 1.58 and leucine 1.50). Only glutamate (2.03) 
had a markedly higher Tumour to NAdj ratio (Supplementary Table S3; Fig. 3). We also compared the mean 
metabolite concentrations from the WT and NAdj tissue samples and found that only glutamate was significantly 
different (Fig. 3). Another approach to quantifying metabolite concentrations is to use the intercept values from 
the linear regression fits, which indicate the mean metabolite contents at the pylorus. Even when there was no 
significant gradient, it was still sometimes possible to demonstrate a statistically significant intercept. For sev-
eral metabolites (glycerophosphocholine, t-Cho, t-Cr, glutamate and leucine) the intercept at the pylorus was 
significantly higher in Tumour samples than NAdj samples (Supplementary Table S2; Supplementary Fig S3). 
Whenever the slope or the intercept of the linear fit of a metabolite was significantly different between Tumour 
and NAdj samples (Supplementary Table S2; Supplementary Fig. S3), the metabolite levels were consistently 
higher in the Tumour compared to NAdj samples (Supplementary Table S3; Fig. 3).
The 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) DNA modification levels, obtained by 
LC/MS, were also tested for topographical gradients. In the Tumour samples there were positive gradients 
from the pylorus for both 5mC and 5hmC (Fig. 4), but only the 5hmC slope was significant at the P < 0.05 level 
(Supplementary Table S4). The slopes of the 5hmC and 5mC gradients were not significantly different when 
comparing WT to NAdj, or NAdj to Tumour (data shown in Supplementary Tables S4, S5). The mean 5hmC and 
5mC data were also tested for differences between the tissue types (Supplementary Table S4; Fig. 4). The overall 
5hmC and 5mC levels were generally lower in Tumour compared to NAdj samples (Fig. 4), with a statistically 
significant difference for 5hmC.
Discussion
The genetic and phenotypical similarities between ApcMin/+ mouse tumours and human intestinal tumours make 
this mouse a good model for studying human bowel  cancer12,13. Two earlier metabolomic studies of ApcMin/+ 
mouse tumours focused on phenotype  determination7 and the effects of a lipid-rich diet on tumour  metabolism14. 
However, no systematic study has reported metabolite gradients along the small intestine of any mouse model.
Our own study was originally intended to test the hypothesis that metabolite concentrations along the length 
of the mouse small intestine are correlated with global DNA cytosine modifications, and that hypothesis turned 
out to be correct. However, we were also surprised to find that there were continuous, linear gradients of metabo-
lite concentrations along the normal, WT mouse small intestine, which were to some extent reproduced in the 
intestinal tumours found at various positions in the small intestines of ApcMin/+ mice. The metabolite concentra-
tion gradients in the WT intestines were all negative, from a maximum at the pylorus to a minimum at the junc-
tion with the large bowel. Negative metabolite gradients were also observed in the tumours and the normal tissue 
adjacent to tumours, with the exception of glycine, which showed a positive gradient in the tumours themselves.
Another unexpected feature of these metabolite gradients was that they were always linear throughout the 
small intestine, rather than being different in the duodenum, jejunum and ileum, as had been found in human 
colon by Wang et al.1. There is also a report of varied epithelial gene and protein expression patterns along the 
human and mouse small intestines, with bicarbonate transporters prominent in the duodenum, where acidic 
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stomach contents are neutralised, digestive enzymes and nutrient transporters highly expressed in the jejunum, 
and bile acid transporters present in the  ileum15. However, Wright and  Alison11 state that rodent small intestine 
Figure 1.  Metabolites that showed a significant concentration gradient in WT (green circles) and tumour 
(red triangles) tissue samples along the length of the mouse small intestine (see Table 1). The p values denote 
whether the gradient slope is significantly different from zero (WT wild-type C57BL/6J, NAdj normal tissue 
adjacent to ApcMin/+ tumours, t-Cho choline + phosphocholine + glycerophosphocholine, t-Cr creatine + 
phosphocreatine).
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does not show a distinct duodenum, jejunum and ileum, which could explain our observations of linear metabolic 
gradients rather than three discontinuous concentrations. Indeed, it has been known for many years that there 
are continuous anatomical gradients along the mouse small  intestine16. The number of intestinal villi shrinks 
from more than 7,000 cells per villus at the pylorus to around 2,000 cells per villus at the distal end, and the 
number of cells per intestinal crypt falls from over 500 cells per crypt near the pylorus to 360 cells per crypt at 
the distal end. The crypt:villus ratio also falls from around 14 crypts per villus in the very proximal bowel to 6 
crypts per villus at the distal  end16. It seems possible, therefore, that these anatomical gradients are associated 
with some of the metabolic gradients that we observed in the WT small intestine, and perhaps also with those 
in Tumour and NAdj samples. However, some metabolites (phosphocholine, glycerophosphocholine, glutamate, 
glycine and taurine) showed no significant gradients in WT samples, and glycine in Tumour samples showed 
a positive gradient (Table 1), which would be difficult to explain on the basis of simple anatomical gradients. 
Figure 2.  Metabolites that showed a significant concentration gradient in normal tissue adjacent to tumours 
along the length of the ApcMin/+ mouse small intestine (see Table 1). The p values denote whether the gradient 
slope is significantly different from zero (t-Cho choline + phosphocholine + glycerophosphocholine, t-Cr 
creatine + phosphocreatine).
Table 1.  Metabolite concentration gradient slopes as a function of distance from the pylorus in wild-
type mice (WT), normal tissue adjacent to ApcMin/+ tumours (NAdj) and Tumours. Statistically significant 
gradients (p < 0.05) are shown in bold t-Cho choline + phosphocholine + glycerophosphocholine, t-Cr, 




Is slope significantly non-zero? p 
values Slope
Is slope significantly non-zero? p 
values Slope
Is slope significantly non-zero? p 
values
Alanine − 0.02 0.0098 NA NA NA NA
Choline − 0.046  < 0.0001 − 0.0383 0.0001 − 0.0091 0.0488
Phosphocholine − 0.0074 0.4522 0.0127 0.235 − 0.0027 0.7327
Glycero− phosphocholine 0.0039 0.666 0.0285 0.0567 0.0079 0.7069
t-Cho − 0.0543 0.0026 − 0.0064 0.7525 − 0.0083 0.6783
Creatine − 0.0373  < 0.0001 − 0.024 0.006 0.0044 0.6887
t-Cr − 0.0286 0.0002 − 0.0196 0.0279 0.0036 0.7023
Glutamate 0.0217 0.0574 0.0007 0.9493 0.0281 0.063
Glycine − 0.002 0.7953 − 0.0176 0.2053 0.0372 0.0067
Taurine 0.0152 0.5038 − 0.0177 0.4637 − 0.0472 0.091
Leucine − 0.0144 0.0105 − 0.0245 0.0018 − 0.0207 0.1024
Valine − 0.0099 0.0182 − 0.0135 0.0241 − 0.0176 0.0301
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Figure 3.  Metabolites that showed an overall significant difference in concentration between WT tissue 
(n = 56), normal tissue adjacent to tumours (NAdj, n = 43) and Tumour (n = 34) tissue samples (WT wild-
type C57BL/6J, NAdj normal tissue adjacent to ApcMin/+ tumours, t-Cho choline + phosphocholine + 
glycerophosphocholine, t-Cr creatine + phosphocreatine. PC + GPC,phosphocholine + glycerophosphocholine).
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Another possibility is that the metabolic gradients we observed might be connected with the gradients in Wnt 
signalling and stem cell number found in mouse and human  intestines17.
In general, fewer Tumour metabolites had concentration gradients than those in the WT or NAdj samples. 
One possible explanation would be that although the tumours originally arose from normal intestinal cells, and 
may initially have displayed the metabolic gradients we found in the normal small intestine, the transformed cells 
were then subjected to metabolic stresses associated with the malignant transformation itself (e.g. disruption of 
tight junctions and dedifferentiation), and with subsequent tumour growth, which could have selected tumour 
cells with genetic differences that over-rode some of the original metabolic gradients.
We also found generally higher metabolite concentrations in tumours than in the NAdj samples. That might 
be due to closer packing of the tumour cells, with e.g. less fat or fibrous tissue in the tumours than in the nor-
mal/healthy intestinal tissues. However, the concentrations of several metabolites (choline, phosphocholine, 
taurine and valine) showed no significant differences between the Tumour and NAdj samples, and glutamate 
was twice as high in the Tumour than in the NAdj samples, whereas the other significantly different metabolite 
concentrations were all in the range 23–58% (Supplementary Table S3), all of which argues against a simple 
anatomical explanation. Glutamate concentrations were also significantly different between the NAdj samples 
and the normal tissue in the same position in the WT small intestine (Fig. 3; Supplementary Table S3). As none 
of the other NAdj metabolite concentrations were significantly different from the WT concentrations (Supple-
mentary Table S3) it seems possible that the high concentration of glutamate in the tumours was diffusing into 
the adjacent tissue. An alternative interpretation would be a field cancerisation effect, a process in which the 
cells in an area of normal tissue are all affected by carcinogenic alterations. Backshall et al. reported metabolic 
alterations in non-tumour gastrointestinal tissue of ApcMin/+ mice with a very low tumour burden, which they 
attributed to field  cancerisation7.
Tumour samples showed a significantly positive glycine gradient along the small intestine (Fig. 1), which 
was the only positive metabolite gradient in any of the three tissues we examined. Increased tumour glycine 
concentrations have previously been found in human colon  cancer5. Glycine can be formed from the glycolytic 
intermediate 3-phosphoglycerate, so it has been suggested that increased glycine in tumour tissues could result 
from a Warburg-like glycolytic phenotype in which cancer cells rely on anaerobic glycolysis even in the presence 
of adequate  oxygen5,18. Glycine is also involved in the folate cycle, which supplies one-carbon units for de novo 
purine synthesis, so increased glycine could enhance nucleotide  synthesis19.
Tumour glutamate was significantly higher than in NAdj samples, and higher in NAdj than in WT samples 
(Supplementary Table S3; Fig. 3). Glutamate, formed by glutaminolysis from glutamine, provides nitrogen for 
synthesis of nucleotides and proteins, which tumours need in large amounts. Increased glutaminolysis is therefore 
Figure 4.  DNA cytosine hydroxymethylation (5hmC) and methylation (5mC) gradient slopes in tumours along 
the length of the small intestine. The p values denote whether the gradient slope was significantly different from 
zero (left column). Overall DNA cytosine modification levels by tissue (right column). DNA modification levels 
obtained in WT (n = 26), NAdj (n = 27) and Tumour (n = 31) tissues.
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considered to be an emerging metabolic hallmark of cancer  metabolism20. Glutamate undergoes transamination 
with pyruvate to form alanine, along with α-ketoglutarate which can enter the tricarboxylic acid cycle (TCA). 
Glycine, too, can enter the TCA via metabolism to pyruvate, as can leucine via metabolism to acetyl-CoA; all 
these metabolites can thus be energy sources or can form metabolites for synthesis of new cancer cells. Choline 
metabolites are involved in phospholipid metabolism and membrane turnover, and are often elevated in tumours, 
while phosphocreatine and creatine form a metabolic energy transfer  system21. Thus the increased mean con-
centration levels of t-Cho, glycine, glutamate, leucine and t-Cr in ApcMin/+ mouse tumours compared to NAdj 
samples are consistent with metabolic reprogramming of phospholipid, amino acid and energy metabolism in 
the tumour tissue.
Cancer cell metabolism is also associated with epigenetic  changes11. The Warburg effect can affect histone 
acetylation and cell proliferation through mechanisms mediated by  butyrate22 and  hydroxybutyrate23, whereas 
other metabolites including S-adenosyl methionine and 2-hydroxyglutarate are required for DNA methyltrans-
ferase (Dnmt) and hydroxylase  activity24. However, we found no 5mC or 5hmC gradients in WT or NAdj tis-
sue, suggesting that the metabolites measured in the small intestine may not limit Dnmt or TET activity. The 
absence of a gradient of 5hmC along the length of the healthy small intestine contrasts with that seen along the 
crypt-villus axis where the low levels of 5hmC in the proliferating progenitors at the crypt base are increased in 
the differentiated epithelium of the  villus8,25–27. This indicates that the ratio of progenitor to differentiated cells 
remains constant along the length of the mouse small intestine.
The reduced 5hmC levels we found in the ApcMin/+ tumours, which are a hallmark of  cancers10,28–36, are con-
sistent with our previous findings in ApcMin/+  adenomas8 and colorectal  cancer37 and more generally with 5hmC 
differences seen in any fast versus slow-proliferating healthy cells and  tissues10. The shallow positive 5hmC 
gradient in Tumours seems to indicate relatively increased 5hmC levels in distal tumours, albeit levels remain 
lower than those in the adjacent normal tissue. The small 5hmC increase may be due to the serine, one-carbon 
cycle, glycine synthesis (SOG) pathway; this concomitantly produces a-ketoglutarate and glycine, which would fit 
with the positive glycine gradient in these tumours. However, the changes in glycine levels were not significantly 
correlated  (R2 = 0.05) with 5hmC levels. We also tested for negative correlations between the 5hmC gradient and 
the negative gradients of choline and valine, but neither was statistically significant.
We found no evidence of reduced 5mC levels in Tumours relative to WT or NAdj samples. Recent genome-
wide analyses have indeed shown equal gains and losses of methylation at regions with differential methylation 
between ApcMin/+ tumours and normal  tissue38. In addition, we have previously shown that 5mC levels are pro-
gressively reduced from normal tissue to adenoma to  adenocarcinoma37, suggesting that marked genome-wide 
changes observed with malignant progression have not taken place in the more benign ApcMin/+ intraepithelial 
adenomas.
conclusions
Normal WT mouse small intestine tissues showed continuous linear negative gradients of the metabolites alanine, 
choline, t-Cho, creatine, leucine and valine, with the highest concentrations in the intestinal tissues adjacent to 
the pylorus. Tumour tissue samples from ApcMin/+ mice showed similar negative gradients of choline and valine, 
but the glycine gradient was positive. The NAdj tissues showed negative gradients in the concentrations of cho-
line, creatine, t-Cr, leucine and valine. There were also increased absolute levels of t-Cho, glycine, glutamate, 
leucine and t-Cr in the tumours when compared to NAdj tissue samples. These metabolic changes are consist-
ent with increased glycolysis and modified phospholipid, amino acid and energy metabolism in the tumours. 
Further work will be necessary to investigate the metabolic origins of these gradients, which could, for instance, 
be connected with regional variations in active or passive uptake and secretion systems of the small intestine.
To our knowledge, this is the first report of measurements of global levels of DNA cytosine modification 
in the ApcMin/+ mouse small intestine. The levels of these epigenetic modifications were similar throughout the 
small intestine, and 5hmC was reduced in the proliferating cells and in tumours. Tumours, however, showed 
positive 5mC and 5hmC gradients from the pylorus, but only the 5hmC slope was statistically significant. These 
epigenetic gradients are likely due to metabolite/nutrient gradient(s) impacting cell proliferation rates. Our 
previous studies in cultured cells and  mice10 have shown that 5hmC levels are highly dependent on the rate of 
cell proliferation (i.e., the average age of the DNA in the cell), as there is a significant time delay between DNA 
methylation during cell replication and 5mC oxidation. Further away from the pylorus there could be lower 
concentration of available nutrients, leading to fewer proliferating tumour cells and therefore higher average 
levels of 5hmC. It is also possible that gradients of metabolites directly affecting TET(s) enzymatic activity 
underly these epigenetic gradients. The TET(s)-mediated oxidation of 5mC to 5hmC can be modulated by the 
concentrations of 2-oxoglutarate, their substrate, or of the competitive inhibitors hydroxyglutarate, fumarate or 
 succinate39,40. The levels of these TET-associated metabolites were below the detection threshold of our NMR 
method in the tissues we have analysed, therefore future lines of investigation would require the use of a more 
sensitive method such as mass spectrometry.
It would also be interesting to repeat earlier studies on rodents or humans that found discrete differences 
in mean metabolite concentrations between the duodenum, jejunum and ileum, in order to see whether these 
mean concentrations had actually been obtained from three regions of continuous gradients in the metabolite 
concentrations.
Methods
Animals and sample collection. ApcMin/+ mice were bred and maintained by backcrossing male Apc-
Min/+ mice with females from a colony of C57BL/6J mice. Tissue samples were taken from normal tissue of 
wild-type C57BL/6J mice (WT), ApcMin/+ adenomatous tumours (Tumour) and from normal tissue adjacent to 
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ApcMin/+ tumours (NAdj). Tissues were dissected under a variable-magnification stereo dissecting microscope, at 
various distances from the pylorus (i.e. the junction with the stomach). WT samples were taken at approximately 
2.8 cm (range 2–4 cm) intervals. In the ApcMin/+ mice, both tumour and Nadj sampling was done according to 
the tumour location, which resulted in an average sampling distance of 2.6 cm (range 1–6 cm). Sample weights 
ranged from 2 to 12 mg, with the smaller samples coming from small adenomas. Samples from the small intes-
tine were a mixture of epithelial and lamina propria cell types. The study approach for sample dissection and 
analysis is shown in Supplementary Fig. S1. Anatomical sites within the mouse small intestine were measured as 
the distance from the pylorus, as advised by Wright and  Alison39.
nMR spectroscopy. HR-MAS 1H NMR of WT, NAdj and Tumour samples was performed on a Bruker 
600 MHz instrument, with a 4 mm HRMAS probe, operated at a spin rate of 3000 Hz and a sample tempera-
ture of 4  °C. LCModel software with a modified basis set was used on water-suppressed spectra to estimate 
the metabolite  concentrations40. Since these were not brain tumours, N-acetyl aspartate and N-acetyl aspartyl 
glutamate were omitted from the analysis. A phosphocreatine signal was simulated in the basis set, since phos-
phocreatine was present in the samples. Absolute metabolite concentrations were quantified relative to the water 
signal observed in each individual  experiment40. This methodology was validated with phantoms containing 
known concentrations of metabolites. NMR data were then obtained from WT (35 samples from 3 animals) 
and ApcMin/+ (43 NAdj and 34 Tumour samples, from 3 animals) tissue samples from mouse small intestines, 
taken at numerous different distances from pylorus to colon. This procedure took 5–10 min per intestine, so we 
performed a separate experiment in which tissues (n = 21 samples from 3 animals) were sampled in the opposite 
direction, from colon to stomach in order to assess possible sampling errors due to tissues that were sampled last 
being subjected to a longer period of ischemia. There was evidence of elevated lactate concentrations in some 
of the samples that had undergone the longest period of ischaemia before freezing, so we have not reported any 
lactate results. None of the other metabolites measured showed any difference in concentration in the samples 
that had been sampled in the reverse direction (Supplementary Fig S2).
In many ex vivo MRS studies, the creatine and choline region signals are quantified as total-creatine and 
total-choline, due to poor resolution of the several metabolite signals in these clusters. We too found that the 
phosphocreatine signals at 3.03 ppm were not consistently observed or resolved from creatine in the HRMAS 1H 
NMR spectra of the tissue samples. Even in samples where phosphocreatine signals were credibly resolved (3 Nadj 
samples), we have therefore added the concentrations of creatine and phosphocreatine together and referred to 
the sum as total creatines (t-Cr). Similarly, the choline, phosphocholine and glycerophosphocholine peaks in the 
3.20–3.23 ppm spectral region could not be resolved in 3 WT, 5 NAdj and 3 Tumour samples, whereas in other 
spectra they were very well resolved. For all samples therefore, we have summed the concentrations of choline, 
phosphocholine and glycerophosphocholine as total choline (t-Cho). However, when the individual peaks of 
the cholines and creatines could be resolved we have also quantified them separately.
Mass spectrometry. Liquid chromatography/mass spectrometry (LC/MS) was performed on DNA 
extracted from tissues recovered after NMR analysis (WT n = 27, NAdj n = 30 and Tumour n = 30) to meas-
ure global levels of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) using methods previously 
 described10,37.
Statistical analysis. All statistical analyses were performed with GraphPad Prism software. Linear regres-
sion models were fitted for each individual metabolite or DNA modification, to investigate whether metabolite 
concentrations and DNA modifications were linearly dependent on distance from the pylorus, and whether this 
varied between WT, NAdj and Tumour samples. The comparisons of interest were NAdj versus WT and NAdj 
versus Tumour.
Linear regression was performed for each metabolite or DNA modification to test for varying intercepts 
and slopes. Where the intercept p value has not been entered (NA), it indicates that the model allows for vary-
ing slopes only, and that there were no significant differences in the intercept. Otherwise, the models allow for 
varying intercepts and slopes.
ethics approval. All experiments were performed under UK Home Office License PPL 80/2427 and all 
procedures were approved by the CRUK Cambridge Institute Animal Welfare and Ethical Review Body.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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